I joined the Laboratory of Cellular and Molecular Neuroendocrinology in 1996 to investigate the neurotrophic effects of PACAP in the developing cerebellum. In 2000, I received a PhD from the University of Rouen under the supervision of Dr Bruno Gonzalez and went for a post-doc in the laboratory of Dr Lee Eiden at the National Institute of Mental Health in Bethesda to investigate the genes regulated by PACAP during PC12 cell differentiation and to characterize the cerebellum of PACAP knock-out mice. In 2002, I was appointed as an INSERM Researcher on a project focusing on the functional evaluation of genes and proteins involved in the neurotrophic effects of PACAP. More recently, I started to develop in collaboration with the team of Pr Alain Fournier, PACAP analogs with improved plasma stability and higher selectivity towards the PAC1 receptor for possible future therapeutic applications for Stroke treatment. I am currently group leader in INSERM Unit 982 and Scientific Manager of PRIMACEN. Our research team now investigates the effects of several factors on cell death and differentiation either during development or in stroke models. My research projects are supported by grants from INSERM, the Agence Nationale de la Recherche (ANR), the Fondation pour la Recherche Médicale (FRM), the Institut de Recherches Scientifiques sur les Boissons (IREB), the Institut pour la Recherche sur la Moelle épinière et l’Encéphale (IRME) and the European Regional Development Fund (ERDF). I have published 99 research papers referenced in Pubmed, including 2 comprehensive reviews in Pharmacological Reviews (2000, 2009), 2 Reviews in Sciences (2002, 2003), 6 PNAS (1999, 2000, 2002, 2005, 2012), 1 Molecular Pharmacology, 5 Journal of Neurochemistry (2002, 2004, 2006, 2006, 2009), 4 Neuroscience (1997,1998, 2007, 2009), 3 J Comp Neurol (2000, 2002, 2007) and 1 J Med Chem (2009).
Biography Updated on 11 March 2013